Recent Price Movement and Market Context
On 25 Nov 2025, Biofil Chemicals & Pharmaceuticals recorded an intraday low of Rs.35.6, representing a 6.32% drop during the trading session. This decline contributed to a four-day losing streak, during which the stock's cumulative return was negative 8.72%. The day’s overall change for the stock was a fall of 2.63%, underperforming the Pharmaceuticals & Biotechnology sector by 5.37% on the same day.
The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend. This contrasts with the broader market, where the Sensex opened 108.22 points higher and was trading at 85,097.53, up 0.23%. The Sensex remains close to its 52-week high of 85,801.70, supported by mega-cap stocks and bullish moving averages.
Long-Term Performance and Comparison
Over the past year, Biofil Chemicals & Pharmaceuticals has recorded a return of -37.91%, significantly trailing the Sensex’s 6.22% gain during the same period. The stock’s 52-week high was Rs.72, highlighting the extent of the recent decline. This underperformance has been consistent over the last three years, with the stock also lagging behind the BSE500 index in each annual period.
Our current Stock of the Month is out! This Large Cap from Automobiles - Passenger Cars emerged as the single best opportunity from our elite universe. Get the details now!
- - Current monthly selection
- - Single best opportunity
- - Elite universe pick
Financial Metrics and Profitability Indicators
Biofil Chemicals & Pharmaceuticals has exhibited a compound annual growth rate (CAGR) of -24.21% in operating profits over the last five years, reflecting a contraction in earnings before interest and taxes (EBIT). The company’s ability to service its debt is limited, with an average EBIT to interest ratio of 0.66, indicating that operating earnings are insufficient to comfortably cover interest expenses.
Return on equity (ROE) averaged 5.27%, suggesting modest profitability relative to shareholders’ funds. Despite these challenges, the company reported positive results for the six months ending recently, with net sales reaching Rs.19.97 crores, representing growth of 84.06% compared to the previous comparable period. Profit after tax (PAT) for the same period was Rs.2.49 crores, showing an increase in absolute terms.
Valuation and Shareholding Structure
The stock is trading at a price-to-book value of 2.9, which is considered attractive relative to its peers’ historical valuations. The company’s ROE for the latest period was 13.4%, indicating an improvement in profitability metrics. Despite the stock’s negative return over the past year, profits have risen by 232%, resulting in a price/earnings to growth (PEG) ratio of 0.1, which may reflect the market’s cautious stance given the company’s overall financial profile.
Majority shareholding is held by non-institutional investors, which may influence trading dynamics and liquidity considerations.
Considering Biofil Chemicals & Pharmaceuticals ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Sector and Market Environment
The Pharmaceuticals & Biotechnology sector has experienced mixed performance, with Biofil Chemicals & Pharmaceuticals notably underperforming its peers. While the broader market indices such as the Sensex maintain a positive trajectory, supported by mega-cap stocks and favourable moving average trends, this stock’s price action diverges from the general market sentiment.
The sector’s dynamics, combined with the company’s financial indicators, have contributed to the stock’s current valuation and price levels. The stock’s decline to Rs.35.6 marks a critical point, representing the lowest price in the past 52 weeks and reflecting the cumulative impact of the company’s financial performance and market conditions.
Summary of Key Price and Performance Data
To summarise, Biofil Chemicals & Pharmaceuticals’ stock has:
- Reached a 52-week low of Rs.35.6 on 25 Nov 2025
- Experienced a four-day consecutive decline with an aggregate return of -8.72%
- Underperformed the Pharmaceuticals & Biotechnology sector by 5.37% on the latest trading day
- Recorded a one-year return of -37.91%, compared to the Sensex’s 6.22%
- Traded below all major moving averages, indicating sustained downward momentum
These factors collectively illustrate the stock’s current position within the market and its relative performance against benchmarks and sector peers.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
